Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Acquired by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lifted its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 453.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,438,908 shares of the company’s stock after purchasing an additional 9,373,412 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 1.37% of Dr. Reddy’s Laboratories worth $180,620,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Bank of Montreal Can increased its position in Dr. Reddy’s Laboratories by 75.4% in the 2nd quarter. Bank of Montreal Can now owns 9,918 shares of the company’s stock valued at $758,000 after acquiring an additional 4,262 shares during the period. Millennium Management LLC increased its position in Dr. Reddy’s Laboratories by 61.4% in the 2nd quarter. Millennium Management LLC now owns 332,502 shares of the company’s stock valued at $25,333,000 after acquiring an additional 126,472 shares during the period. Creative Planning increased its position in Dr. Reddy’s Laboratories by 22.6% in the 2nd quarter. Creative Planning now owns 87,522 shares of the company’s stock valued at $6,668,000 after acquiring an additional 16,157 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its position in Dr. Reddy’s Laboratories by 318.0% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company’s stock valued at $28,411,000 after acquiring an additional 283,700 shares during the period. Finally, GAMMA Investing LLC increased its position in Dr. Reddy’s Laboratories by 83.2% in the 3rd quarter. GAMMA Investing LLC now owns 1,447 shares of the company’s stock valued at $115,000 after acquiring an additional 657 shares during the period. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on RDY shares. StockNews.com cut Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Nomura cut Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. Finally, Barclays decreased their price target on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th.

Dr. Reddy’s Laboratories Stock Performance

Shares of NYSE RDY opened at $13.52 on Wednesday. The stock has a fifty day moving average price of $14.84 and a two-hundred day moving average price of $15.49. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.36 and a current ratio of 1.92. The firm has a market cap of $11.29 billion, a P/E ratio of 21.60 and a beta of 0.51. Dr. Reddy’s Laboratories Limited has a 1 year low of $13.36 and a 1 year high of $16.89.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 18.53% and a net margin of 17.81%. Research analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.81 EPS for the current fiscal year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.